Market Overview

Bayer HealthCare to Acquire US Animal Health Business From Teva Pharmaceutical Industries


Bayer HealthCare and Teva Pharmaceutical Industries (NYSE: TEVA) announced today that they have signed an agreement in which Bayer
will acquire the U.S. based animal health business of Teva for up to 145
million USD. The purchase price includes an upfront payment of 60
million USD plus a total of 85 million USD in milestone payments, which
are linked to the successful and timely achievement of manufacturing and
sales targets. The acquisition allows Bayer to expand its companion and
food animal product lines in the United States by integrating the
acquired assets into its animal health business. The transaction
reflects Teva's commitment to focus its efforts on human health and its
core expertise of providing generic and branded medicines to patients
around the world.

See full press release

Posted-In: News Guidance Asset Sales M&A Global


Related Articles (TEVA)

View Comments and Join the Discussion!

Partner Center